NeoStem Ranked Number 1 Fastest Growing Company in the Tri-State Region on Deloitte’s 2012 Technology Fast 500(TM)

NeoStem, Inc. (NYSE MKT:NBS) (“NeoStem” or the “Company”), an emerging market leader in the fast growing cell therapy industry, today announced it ranked number 1 in the Tri-State region and number 7 nationally on Deloitte’s 2012 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.

Dr. Robin L. Smith, NeoStem’s Chairman and CEO, said “We are proud to be recognized for this achievement as we build NeoStem into a top tier biopharmaceutical company and thrilled to be honored alongside such fast-growing, successful companies such as Celgene, LinkedIn, and Google. On behalf of the entire NeoStem team, I would like to thank Deloitte & Touche, LLP for their recognition of our efforts.”

NeoStem is emerging as a market leader in the fast growing cell therapy industry. The Company’s multifaceted business strategy combines a state-of-the-art contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program providing for near- and long-term revenue growth opportunities. We focus on developing cell therapy products around a strong IP portfolio. These products are focused on large markets such as cardiovascular disease, autoimmune disorders and regenerative medicine.

In a challenging economy with risk adverse capital markets, we have fashioned a management team that is both flexible and opportunistic. PCT, acquired in 2011, expands our  revenue growth and gives us unique insight into the clinical and commercial cell therapy manufacturing market while we simultaneously develop our own clinical products. This service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries.

NeoStem is focused on organic growth and continuously evaluates strategic opportunities. We look forward to achieving success for our future patients, our PCT clients, employees and shareholders.

上一篇 下一篇